eid tuberculosis

32
7/23/2019 EID Tuberculosis http://slidepdf.com/reader/full/eid-tuberculosis 1/32   Mycobacterium species Acid fast bacilli - cell walls contain unusual glycolipids (e.g.mycolic acids)

Upload: akmal-hakim

Post on 18-Feb-2018

222 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 1/32

 

 Mycobacterium species

Acid fast bacilli - cell walls contain unusual glycolipids

(e.g.mycolic acids)

Page 2: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 2/32

 

 Mycobacterium species

Acid fast bacilli - cell walls contain unusual glycolipids

(e.g.mycolic acids)

Intracellular organisms (some are facultative others are obligate)

Page 3: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 3/32

 

Diseases caused by Mycobacterium species

 M. tuberculosis - tuberculosis

 M. leprae - leprosy

Page 4: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 4/32

 

Diseases caused by Mycobacterium species

 M. avium - lung and skin infections in immunocompromised

hosts

  - lymphadenopathy in children

  - catheter-related infections

Page 5: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 5/32

 

 Mycobacterium tuberculosis

Closely related to M. bovis (a cattle parasite/pathogen?)

 M. tuberculosis believed to have evolved from M. bovis after

domestication of cattle (8,000-4,000 BC)

Archeologists have shown that tuberculosis of the bones seems to

have preceded the disease of the lungs

Page 6: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 6/32

 

Tuberculosis (TB)

Most common cause of death due to bacterial infection worldwide

2 billion infected worldwide / 8-9 million new cases per year

Aggressive measures decreased infections in developed countries

Page 7: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 7/32

 

Tuberculosis (TB)

Page 8: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 8/32

 

TB

Once known as consumption

Afflicted individuals considered

beautiful and erotic

Thought that TB sparked genius

Page 9: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 9/32

 

TB

Spread by aerosols

Symptoms include : fever

  coughing (often with blood)

  weight loss

  malaise (loss of energy)

  → progressive lung damage

Page 10: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 10/32

 

Systemic TB

Can infect any area of the body including:

Bones and joints

Internal organs

Brain

Page 11: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 11/32

 

Progression of TB

 M. tuberculosis can survive within unactivated macrophages

Activated macrophages can kill the bacteria

Individual’s immunological response determines the outcome of

exposure

Page 12: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 12/32

 

Progression of TB

T-cells involved in controlling infection

Gamma interferon (IFN-γ ) activates macrophages

Cytotoxic T-cells (Tc -cells) kill infected macrophages

Page 13: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 13/32

 

Progression of TB

Healthy individual exposed to low dose

→ activated macrophages stop infection

Individuals unable to mount a rapid response

→ bacteria multiply in lung macrophages

Page 14: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 14/32

 

Progression of TB

Individuals unable to mount a rapid response

→ bacteria multiply in lung macrophages

→ phagocytes attracted to site of infection

→ infection may be walled-off/ forms tubercle

Tubercles may calcify and become visible in chest X-rays(Ghon complex)

Page 15: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 15/32

 

Ghon complex

Page 16: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 16/32

 

Progression of TB

Continuous growth of bacteria causes interior of tubercle to

liquefy

Rupture of tubercle allows bacteria to escape

Leads to infection of others (aerosols) or other parts of the body

Page 17: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 17/32

 

Progression of TB

Page 18: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 18/32

 

Progression of TB

Page 19: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 19/32

 

Progression of TB

Page 20: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 20/32

 

Progression of TB

Bacteria in tubercles may survive for decades (latency)

Suppression of immune system may allow bacteria to break out

of lesions and multiply (reactivation)

Old age, cancer, immunosuppressive drugs and HIV infection

can lead to reactivation

Page 21: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 21/32

 

Virulence factors

Invasion of and survival within phagocytes

Interference with T-cell activation

Eliciting inflammatory response

Page 22: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 22/32

 

Diagnosis of TB

Acid-fast staining of sputum samples

Page 23: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 23/32

 

Diagnosis of TB

TB skin test - injection of M. tuberculosis proteins (tuberculin)

  - positive test leads to red area at injection site

Page 24: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 24/32

 

Treatment of TB

Streptomycin - first antibiotic used against M. tuberculosis

- did not always cure patients

- slowly dividing cells became resistant

Page 25: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 25/32

 

Treatment of TB

Rifampin - used to treat TB and prophylactically for bacterial

meningitis

  - resistant mutants arise readily

- used in combination with other drugs

Page 26: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 26/32

 

 M. tuberculosis specific drugs

Isoniazid - isonicotinic acid hydrazide or INH

  - must be converted into the active form by a bacterial

enzyme (catalase-peroxidase)

  - inhibits the formation of mycolic acid

  - resistance occurs by inactivation of catalase-

  peroxidase or by mutation of enzyme in mycolic acid

synthesis pathway

Page 27: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 27/32

 

 M. tuberculosis specific drugs

Pyrazinamide - bacterial enzyme (PZase) converts it to

pyrazinoic acid (active form)

- target of the drug is unknown

- uptake increases under acidic conditions

(vacuoles of phagocytes)

- targets bacteria inside phagocytic cells

- lowered activity of PZase results in resistance

Page 28: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 28/32

 

DOTS - directly observed therapy short course

System in which patients were monitored by health care workers

to ensure they took their medications

Cocktail of different drugs are required to ensure resistant strains

do not arise

Page 29: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 29/32

 

Development of resistant M. tuberculosis

DOTS system dismantled in the 1970s

Rise in prison population

Rise in the homeless living in crowded shelters

Page 30: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 30/32

 

Development of resistant M. tuberculosis

Physicians no longer trained to diagnose and treat TB

Organisms exist in different compartments and exhibit different

metabolic activities → one or more drug may not be effective

Page 31: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 31/32

 

Multidrug resistant tuberculosis (MDR-TB)

Defined as the presence of M. tuberculosis resistant to at least

isoniazid and rifampicin

Treatment involves use of “second line” drugs

Some of these were first line antituberculosis drugs when they

were first introduced

(e.g. Streptomycin and p-Aminosalicylic acid (PAS))

Page 32: EID Tuberculosis

7/23/2019 EID Tuberculosis

http://slidepdf.com/reader/full/eid-tuberculosis 32/32

Multidrug resistant tuberculosis (MDR-TB)

Good diagnostics is critical in controlling MDR-TB

DOTS Plus strategy - includes monthly monitoring of patients for

presence of resistant strains and changing drug regimen as

resistance status changes